Carregant...
First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a complex disease with a poor prognosis. Selexipag is a selective prostacyclin receptor agonist with vasodilatory, anti-proliferative, anti-inflammatory, and pro-angiogenic properties. However, no clinical data on its therapeutic use in children with PAH are...
Guardat en:
| Publicat a: | Pulm Circ |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5467934/ https://ncbi.nlm.nih.gov/pubmed/28597771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045893217703369 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|